Neurana appears to be having success in the development of a non-opioid pain reliever using Tolperisone for acute muscle spasms. They are now in phase 3 trials. Neurana is a privately held company. Does anyone know who their industry partner might be? Any ideas on how to invest in their future upside before they get purchased or do an IPO?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Also I forgot to mention that Neurana is partnered with Sanochemia Pharmazeutika (Austria) using their drug, Tolperisone. Sanochemia is not public either, I believe. From Sanochemia’s website:Neurology
Tolperisone is a muscle relaxant developed for the treatment of acute, painful muscle spasms for back pain and spasticity in neurological diseases.
Through a unique mechanism of action, tolperisone acts dual: on the one hand on the peripheral neural system, on the other hand on the spinal cord and the brain stem. This relieves severe muscle spasms and improves patient mobility. Although tolperisone is centrally effective, it has little sedation potential.
Tolperisone has been licensed to Neurana Pharmaceuticals and is currently undergoing clinical development. SANOCHEMIA’s partner Neurana Pharmaceuticals has successfully completed the Phase 2 clinical trial in 2019 and plans to launch the Phase 3 clinical trial of tolperisone in 2020.